Emmaus Life Sciences Files 8-K on Officer/Director Changes
Ticker: EMMA · Form: 8-K · Filed: Oct 4, 2024 · CIK: 822370
| Field | Detail |
|---|---|
| Company | Emmaus Life Sciences, INC. (EMMA) |
| Form Type | 8-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, officer-appointment, director-election, financial-statements
TL;DR
Emmaus Life Sciences 8-K: Leadership changes and financial updates filed as of Sept 30, 2024.
AI Summary
Emmaus Life Sciences, Inc. filed an 8-K on October 4, 2024, reporting on events as of September 30, 2024. The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It also includes financial statements and exhibits.
Why It Matters
This filing provides crucial updates on the company's leadership and executive compensation, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Changes in corporate leadership and the filing of financial statements can indicate significant internal shifts or upcoming financial performance, requiring investor attention.
Key Players & Entities
- Emmaus Life Sciences, Inc. (company) — Registrant
- September 30, 2024 (date) — Date of earliest event reported
- October 4, 2024 (date) — Filing Date
- MYnd Analytics, Inc. (company) — Former Company Name
- CNS RESPONSE, INC. (company) — Former Company Name
- STRATIVATION, INC. (company) — Former Company Name
FAQ
What specific officer or director positions were affected by the changes reported in this 8-K?
The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" but does not specify names or positions within the provided text.
What is the significance of the 'Compensatory Arrangements of Certain Officers' mentioned?
This item suggests that the filing includes details regarding the compensation packages or agreements for key executives within Emmaus Life Sciences, Inc.
When was the earliest event reported in this filing?
The earliest event reported was as of September 30, 2024.
What are the former names of Emmaus Life Sciences, Inc.?
Emmaus Life Sciences, Inc. was formerly known as MYnd Analytics, Inc., CNS RESPONSE, INC., and STRATIVATION, INC.
What type of information is included in the 'Financial Statements and Exhibits' section of this filing?
This section indicates that the filing contains financial statements and other relevant exhibits pertaining to Emmaus Life Sciences, Inc.
Filing Stats: 656 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-10-04 17:23:17
Filing Documents
- ea0216701-8k_emmaus.htm (8-K) — 26KB
- 0001213900-24-085641.txt ( ) — 191KB
- emma-20240930.xsd (EX-101.SCH) — 3KB
- emma-20240930_lab.xml (EX-101.LAB) — 33KB
- emma-20240930_pre.xml (EX-101.PRE) — 22KB
- ea0216701-8k_emmaus_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the inline XBRL Document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 4, 2024 EMMAUS LIFE SCIENCES, INC. By: /s/ YASUSHI NAGASAKI Name: Yasushi Nagasaki Title: Chief Financial Officer 2